Sept. 30, 2021 Price forecast | 2 weeks: -1.34% | 1 month: -2.64% | 3 months: 17.26% | Premium Forecast


ADMA stock forecast

Our latest prediction for Adma Biologics Inc's stock price was made on the Sept. 30, 2021 when the stock price was at 1.13$.

In the short term (2weeks), ADMA's stock price should underperform the market by -1.34%. During that period the price should oscillate between -13.31% and +14.42%.

In the medium term (3months), ADMA's stock price should outperform the market by 17.26%. During that period the price should oscillate between -43.15% and +53.75%.

Create a solid portfolio with ADMA

Add ADMA to your portfolio and optimize it!


About Adma Biologics Inc

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates.

At the moment the company generates 58M USD in revenues.

On its last earning announcement, the company reported a loss of -0.70$ per share.

The book value per share is 1.12$

Adma Biologics Inc website


Three months stock forecastSept. 30, 2021


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
58M -16.30% -62M -106.30% -74M -0.70 - - 107M 1.12 -122M -14M -135M